IP Library Granted Patent US 7,566,713
Granted Patent B2
US 7,566,713 · App. 11/597,319 · Granted Jul 28, 2009

Immuno inhibitory heterocyclic compounds

Assignee: Medigene Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,566,713
App. No.
11/597,319
Granted
Jul 28, 2009
Kind
B2
Abstract

Compounds of formula (I) are CD80 inhibitors, and of value for immunomodulation, e.g. in rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis: wherein Y is —CH 2 —, —CH 2 CH 2 —, or CH 2 CH 2 CH 2 —; R 1 represents H; F; methyl, trifuoromethyl, methoxy or triflioromethoxy; R 3 represents H; F; CI; Br; NO 2 ; CN; C 1 C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F; R 4 represents a carboxylic acid group (—COOH) or an ester thereof, or —C(═O) NR 6 R 7 —NR 7 C(═O)R 6 , NR 7 C(═O)OR 6 , NHC(═O) or NHC(═S)NR 7 R 6 wherein R 6 and R 7 are as defined in the specification and X represents a bond or a divalent radical as defined in the specification.

Claims (36)

1. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:

wherein

Y is —CH 2 —, —CH 2 CH 2 —, or —CH 2 CH 2 CH 2 —;

R 1 represents H; F; methyl, trifluoromethyl, methoxy or trifluoromethoxy;

R 3 represents H; F; Cl; Br; —NO 2 ; —CN; C 1 -C 6 alkyl optionally substituted by F or Cl; or C 1 -C 6 alkoxy optionally substituted by F;

R 4 represents a carboxylic acid group (—COOH) or an ester group of formula COOR wherein R is methyl, ethyl, n- or iso-propyl, n-, sec-, or tert-butyl or benzyl, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or —NHC(═S)NR 7 R 6 wherein

R 6 represents H, or a radical of formula -(Alk) m -Q wherein

m is 0 or 1

Alk is an optionally substituted divalent straight or branched C 1 -C 12 alkylene, or C 2 -C 12 alkenylene, or C 2 -C 12 alkynylene radical or a divalent C 3 -C 12 carbocyclic radical, any of which radicals may be interrupted by one or more —O—, —S— or —N(R 8 )- radicals wherein R 8 represents H or C 1 -C 4 alkyl, C 3 -C 4 alkenyl, C 3 -C 4 alkynyl, or C 3 -C 6 cycloalkyl, and

Q represents H; —NR 8 R 8 wherein each R 8 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group of formula COOR wherein R is methyl, ethyl, n- or iso-propyl, n-, sec-, or tert-butyl or benzyl; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; and

R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms; and

X represents a bond or a divalent radical of formula -(Z) n -(Alk)- or -(Alk)-(Z) n - wherein Z represents —O—, —S— or —NH—, Alk is as defined in relation to R 6 and n is 0 or 1.

2. A compound as claimed in claim 1 wherein Y is —CH 2 CH 2 —.

3. A compound as claimed in claim 1 wherein the radical R 4 X— is in the 4-position of the phenyl ring.

4. A compound as claimed in claim 1 wherein X is a bond.

5. A compound as claimed in claim 1 wherein R 3 is hydrogen.

6. A compound as claimed in claim 1 wherein R 1 is hydrogen or fluoro.

7. A compound as claimed in claim 1 wherein R 4 represents —C(═O)NR 6 R 7 .

8. A compound as claimed in claim 1 wherein R 4 represents —NHC(═O)NR 7 R 6 .

9. A compound as claimed in claim 1 wherein R 6 represents a radical of formula -(Alk) m -Q wherein m is 1 and the divalent radical Alk contains 3 or 4 carbon atoms and is unsubstituted, and Q represents —NR 8 R 8 wherein each R 8 independently represents H; C 1 -C 4 alkyl; C 3 -C 4 alkenyl; C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group of formula COOR wherein R is methyl, ethyl, n- or iso-propyl, n-, sec-, or tert-butyl of benzyl; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted.

10. A compound as claimed in claim 9 wherein Q is a quinuclidine radical.

11. A compound as claimed in claim 7 wherein R 7 is hydrogen.

12. A compound as claimed in claim 1 wherein R 6 represents a radical of formula -(Alk) m -Q wherein m is 1, Alk is —CH 2 —, —CH 2 CH 2 , —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 3 )CH 2 —, or a divalent cyclopropylene, cyclopentylene or cyclohexylene radical, optionally substituted by OH, oxo, CF 3 , methoxy or ethoxy, and Q represents hydrogen; —NR 8 R 8 wherein each R 8 may be the same or different and selected from hydrogen, methyl, ethyl, n- or isopropyl or tert-butyl; a methyl, ethyl or benzyl ester; or an optionally substituted phenyl, phenoxy, cyclopentyl, cyclohexyl, furyl, thienyl, piperidyl, or piperazinyl group.

13. A compound as claimed in claim 1 wherein R 7 represents methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.

14. A compound as claimed in claim 1 wherein R 1 is F, in the 6-position of the 3-oxo-1,3-dihydro-2H-pyrazolo[4,3-c]cinnolin-2-yl ring system.

15. A compound as claimed in claim 1 wherein X is a bond, or a —CH 2 — or —CH 2 CH 2 — radical.

16. A compound of formula (IC) or a pharmaceutically or veterinarily acceptable salt thereof:

wherein X is a bond, or a —CH 2 — or —CH 2 CH 2 — radical and R 4 represents a carboxylic acid group (—COOH) or an ester group of formula COOR wherein R is methyl, ethyl, n- or iso-propyl, n-, sec- or tert-butyl or benzyl, or —C(═O)NR 6 R 7 , —NR 7 C(═O)R 6 , —NR 7 C(═O)OR 6 , —NHC(═O)NR 7 R 6 or

—NHC(═S)NR 7 R 6 wherein

R 6 represents a radical of formula -(Alk) m -Q wherein m is 1 and

the divalent radical Alk contains 3 or 4 carbon atoms and is unsubstituted, and Q represents —NR 8 R 8 wherein each R 8 independently represents H; C 1 -C 4 alkyl; C 1 -C 4 alkenyl, C 3 -C 4 alkynyl; C 3 -C 6 cycloalkyl; an ester group; an optionally substituted carbocyclic or heterocyclic group; or form a ring when taken together with the nitrogen to which they are attached, which ring is optionally substituted; or

Alk is —CH 2 —, —CH 2 CH 2 , —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 3 )CH 2 —, or a divalent cyclopropylene, cyclopentylene or cyclohexylene radical, optionally substituted by OH, oxo, CF 3 , methoxy or ethoxy, and Q represents hydrogen; —NR 8 R 8 wherein each R 8 may be the same or different and selected from hydrogen, methyl, ethyl n- or isopropyl or tert-butyl; a methyl, ethyl or benzyl ester; or an optionally substituted phenyl, phenoxy, cyclopentyl, cyclohexyl, furyl, thienyl, piperidyl, or piperazinyl group; and

R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form an optionally substituted monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.

17. A compound as claimed in claim 15 wherein the radical R 4 X— is in the 4-position of the phenyl ring.

18. A compound as claimed in claim 16 wherein X is a bond and R 4 is —C(═O)NR 6 R 7 wherein R 6 represents a radical of formula —(Alk) m -Q wherein m is 1 Alk is —CH 2 —, —CH 2 CH 2 , —CH 2 CH 2 CH 2 —, or —CH 2 CH(CH 3 )CH 2 —, or a divalent cyclopropylene, cyclopentylene or cyclohexylene radical, optionally substituted by OH, oxo, CF 3 , methoxy or ethoxy, and Q represents hydrogen and R 7 represents H or C 1 -C 6 alkyl; or when taken together with the atom or atoms to which they are attached R 6 and R 7 form a monocyclic heterocyclic ring having 5, 6 or 7 ring atoms.

19. A pharmaceutical or veterinary composition comprising a compound as claimed in claim 1 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2011
From: MEDIGENE LIMITED
To: MEDIGENE AG
Reel/Frame 025938/0048 →
CHANGE OF NAME Recorded Sep 23, 2008
From: AVIDEX LIMITED
To: MEDIGENE LIMITED
Reel/Frame 021569/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2007
From: MATHEWS, IAN RICHARD
To: AVIDEX LTD.
Reel/Frame 019904/0238 →
Priority Claims (1)
GB 0411770.1 · May 26, 2004 · national
Continuity (1)
Related Publication 20080021033A1 · Jan 24, 2008